September 16, 2019
Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm
Media
September 15, 2019
New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop
September 12, 2019
Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting
September 11, 2019
Vicore Pharma has been approved for listing on Nasdaq Stockholm
September 09, 2019
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
September 06, 2019
Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
September 04, 2019
Nordic Nanovector to participate in three upcoming investor conferences in the US
September 03, 2019
Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019
August 30, 2019
New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th
August 29, 2019
Nordic Nanovector ASA: Invitation to R&D Day in Oslo and Webcast